• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Angiotensin II inhibition and prevention of atrial fibrillation and stroke.

作者信息

Bourassa Martial G

出版信息

J Am Coll Cardiol. 2005 Mar 1;45(5):720-1. doi: 10.1016/j.jacc.2004.12.008.

DOI:10.1016/j.jacc.2004.12.008
PMID:15734616
Abstract
摘要

相似文献

1
Angiotensin II inhibition and prevention of atrial fibrillation and stroke.血管紧张素II抑制与心房颤动及中风的预防
J Am Coll Cardiol. 2005 Mar 1;45(5):720-1. doi: 10.1016/j.jacc.2004.12.008.
2
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.与阿替洛尔相比，血管紧张素II受体阻滞剂可降低新发房颤及后续卒中风险：氯沙坦干预降低高血压终点事件研究（LIFE研究）。
J Am Coll Cardiol. 2005 Mar 1;45(5):712-9. doi: 10.1016/j.jacc.2004.10.068.
3
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.有房颤病史的高血压患者的心血管发病率和死亡率：氯沙坦干预降低高血压终点事件（LIFE）研究
J Am Coll Cardiol. 2005 Mar 1;45(5):705-11. doi: 10.1016/j.jacc.2004.06.080.
4
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.在氯沙坦干预降低高血压终点事件（LIFE）研究中，氯沙坦对中风有益的潜在机制。
Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435.
5
[Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].中风、心房颤动、糖尿病和肾功能不全的病例减少。良好的高血压治疗不仅仅是降低血压。
MMW Fortschr Med. 2008 Jan 17;150(1-2):52-3.
6
Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.高血压患者心房颤动发生率与心率随时间变化的关系：LIFE研究
Circ Arrhythm Electrophysiol. 2008 Dec;1(5):337-43. doi: 10.1161/CIRCEP.108.795351. Epub 2008 Dec 2.
7
[Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].[心房颤动患者的高血压治疗。沙坦类药物优于β受体阻滞剂]
MMW Fortschr Med. 2003 May 8;145(19):53.
8
Can losartan prevent new-onset atrial fibrillation in hypertensive patients more effectively than atenolol?
Nat Clin Pract Cardiovasc Med. 2005 Jul;2(7):332-3. doi: 10.1038/ncpcardio0247.
9
[LIFE study proves preventive action. With losartan to do even more against stroke].
MMW Fortschr Med. 2003;145 Suppl 1:7-8.
10
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.高血压左心室肥厚患者氯沙坦干预降低终点事件（LIFE）研究中的血压降低及降压药物使用情况
Curr Med Res Opin. 2007 Feb;23(2):259-70. doi: 10.1185/030079906X162854.

引用本文的文献

1
Industry pulse : editorial development by adis international limited, Italy.
High Blood Press Cardiovasc Prev. 2005 Sep;12(3):195-8. doi: 10.2165/00151642-200512030-00174.
2
QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction.QRS 时限与左心功能障碍患者的心房颤动有关。
Clin Cardiol. 2010 Mar;33(3):132-8. doi: 10.1002/clc.20714.
3
Rate versus rhythm control strategies for AF.
Curr Treat Options Cardiovasc Med. 2005 Oct;7(5):371-81. doi: 10.1007/s11936-005-0021-3.